Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis.

Paediatric respiratory reviews - 1 Sept 2017

Aslam Aisha, Jahnke Nikki, Remmington Tracey, Southern Kevin W

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cystic Fibrosis
Share to Cystic Fibrosis Transmembrane Conductance Regulator
Share to Mutation
Share to Oxadiazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Randomized Controlled Trials as Topic

Share to Risk Assessment

Share to Treatment Outcome

Source

Identifiers

PMID: 28566196
DOI: 10.1016/j.prrv.2017.04.001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis.PMID 28566196Read ↗

Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosisSemantic proximity Read ↗

Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis.Semantic proximity Read ↗

Ataluren in cystic fibrosis: development, clinical studies and where are we now?Semantic proximity Read ↗

Ataluren: first global approval.Semantic proximity Read ↗

Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: The international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF)Semantic proximity Read ↗

European Medicines Agency review of ataluren for the treatment of ambulant patients aged 5 years and older with Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin geneSemantic proximity Read ↗

Elexacaftor/Tezacaftor/Ivacaftor Effectiveness in N1303K Variant in Adult People With Cystic Fibrosis.Semantic proximity Read ↗

New Pharmacological Approaches to Treat Patients with Cystic Fibrosis with Nonsense Mutations.Semantic proximity Read ↗

Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosisSemantic proximity Read ↗

Pharmacological approaches for targeting cystic fibrosis nonsense mutations.Semantic proximity Read ↗

Tezacaftor-ivacaftor is safe and efficacious in patients with cystic fibrosis with Phe508del mutations.Semantic proximity Read ↗

Advances in the design and discovery of novel small molecule drugs for the treatment of Dravet Syndrome.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.